Study: This $4 Generic Antidepressant Significantly Reduces COVID-19 Hospitalizations

An inexpensive, generic antidepressant has been shown to significantly reduce the risk of severe COVID-19 in clinical trials.

Fluvoxamine — a readily available pill used to treat depression and obsessive-compulsive disorder — dramatically reduces serious illness and death from COVID-19 when prescribed early, according to a study published in the journal Lancet Global Health.

There were 1,497 COVID-positive patients in Brazil involved in the study; 741 patients were given fluvoxamine and 756 were given a placebo. The study — which was performed from Jan. 20 until Aug. 5 — found that patients who received fluvoxamine saw their hospitalizations or long-term medical observation rates decrease by nearly one-third.

The clinical trial found using the antidepressant for 10 days decreased the absolute risk by 5%, and there was a relative risk reduction of 32% compared to the control group. (Read more from “This $4 Generic Antidepressant Significantly Reduces COVID-19 Hospitalizations” HERE)

Photo credit: https://www.flickr.com/photos/91261194@N06/51021133488

Delete Facebook, Delete Twitter, Follow Restoring Liberty and Joe Miller at gab HERE.